Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial.
Saved in:
| Title: | Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial. |
|---|---|
| Authors: | Wu W; Breast Tumor Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangzhou, PR China., Yang Y; Breast Tumor Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangzhou, PR China., Chen H; Breast Tumor Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangzhou, PR China., Lu Y; Department of Breast, Bone and Soft Tissue Oncology, Guangxi Medical University Cancer Hospital, Nanning, PR China., Zeng Y; Breast Tumor Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangzhou, PR China., Zhao J; Breast Tumor Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangzhou, PR China., Du C; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, PR China., Lin Y; Breast Disease Center, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, PR China., Peng P; Department of Breast Disease, The Fifth Affiliated Hospital of Sun-Yat-Sen University, Zhuhai, PR China., Huang M; Department of Breast Disease, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, PR China., Zhang Y; Cancer Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, PR China., Ouyang Q; Department of Breast Medicine, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, PR China., Ding L; Breast Tumor Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangzhou, PR China., Cheng Z; Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China., Wen Y; Breast Tumor Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangzhou, PR China., Wu Z; Breast Disease Diagnosis and Treatment Center, Shantou Central Hospital, Shantou, PR China., Ye J; Department of Breast Disease, The First People's Hospital of Zhaoqing, Zhaoqing, PR China., Ling L; Clinical Research Design Division, Clinical Research Center, Sun Yat-sen Memorial Hospital, School of Public Health, Sun Yat-sen University, Guangzhou, PR China., Wang K; Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, PR China., Lu Y; Department of Oncology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, PR China., Zou G; Department of Oncology, The Affiliated Panyu Central Hospital of Guangzhou Medical University, Guangzhou, PR China., Zhong J; Department of Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, PR China., Wang H; Department of Oncology, Nanchang People's Hospital, Nanchang, PR China., Lin D; Department of Oncology, Jiangmen Central Hospital, Jiangmen, PR China., Zeng; The Second Department of Internal Medicine, Cancer Hospital of Shantou University Medical College, Shantou, PR China., Yao C; Department of Breast Surgery, Sixth Affiliated Hospital of South China University of Technology, and Sixth Clinical College of South China University of Technology, Foshan, PR China., Chen Q; State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, PR China.; Department of Breast, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, PR China., Zou L; Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, PR China., Wang S; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, PR China., Yu Y; Department of Medical Oncology, Phase I Clinical Trial Centre, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China.; Guangdong Provincial Key Laboratory of Cancer Pathogenesis and Precision Diagnosis and Treatment, Joint Big Data Laboratory, Department of Medical Oncology, Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, PR China., Yuan Z; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, PR China. yuanzhy@sysucc.org.cn., Wang Y; Breast Tumor Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangzhou, PR China. yingwang1101@126.com., Yao H; Breast Tumor Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangzhou, PR China. yaoherui@mail.sysu.edu.cn.; Department of Medical Oncology, Phase I Clinical Trial Centre, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China. yaoherui@mail.sysu.edu.cn. |
| Source: | Signal transduction and targeted therapy [Signal Transduct Target Ther] 2026 May 22; Vol. 11 (1). Date of Electronic Publication: 2026 May 22. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101676423 Publication Model: Electronic Cited Medium: Internet ISSN: 2059-3635 (Electronic) Linking ISSN: 20593635 NLM ISO Abbreviation: Signal Transduct Target Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2059-3635 |
|---|---|
| DOI: | 10.1038/s41392-026-02720-6 |
